Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.N Engl J Med. 2004; 350: 2140-2150
- The effect of cardiac resynchronization on morbidity and mortality in heart failure.N Engl J Med. 2005; 352: 1539-1549
- 2017 ACC/AHA/HFSA Focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.J Card Fail. 2017; 23: 628-651
- Effectiveness of cardiac resynchronization therapy in heart failure patients with valvular heart disease: comparison with patients affected by ischaemic heart disease or dilated cardiomyopathy. The InSync/InSync ICD Italian Registry.Eur Heart J. 2009; 30: 2275-2283
- Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT).Circulation. 2011; 124: 1527-1536
- Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials.Am Heart J. 2006; 151: 837-843
- Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy.Circulation. 2010; 122: 2660-2668
- Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study.Eur Heart J. 2009; 30: 2109-2116
- Prognostic value of brain natriuretic peptide in the management of patients receiving cardiac resynchronization therapy.Eur J Heart Fail. 2006; 8: 509-514
- Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels.Eur J Heart Fail. 2007; 9: 1058-1063
- Plasma tissue inhibitor of matrix metalloproteinase-1 (TIMP-1): an independent predictor of poor response to cardiac resynchronization therapy.Eur J Heart Fail. 2010; 12: 492-498
- Usefulness of preimplantation B-type natriuretic peptide level for predicting response to cardiac resynchronization therapy.Am J Cardiol. 2007; 99: 242-246
- Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders.Eur J Heart Fail. 2013; 15: 1277-1288
- Effects of cardiac resynchronization therapy on systemic inflammation and neurohormonal pathways in heart failure.Cardiol J. 2009; 16: 545-552
- The IL-33/ST2 pathway—a new therapeutic target in cardiovascular disease.Pharmacol Ther. 2011; 131: 179-186
- Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure.Circ Heart Fail. 2011; 4: 246-256
- Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study.Eur Heart J. 2004; 25: 1509-1516
This work was supported by National Institutes of Health Grant HL095608 (FGS), a Merit Award from the Veterans’ Affairs Health Administration to Dr Spinale, and an unrestricted grant from Boston Scientific to Dr Spinale. Dr Meyer, Dr Stolen, Mr Wold, and Dr Stein are employees of Boston Scientific. ClinicalTrials.gov Identifier: NCT00677014.